Andreas Schlicker
Overview
Explore the profile of Andreas Schlicker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
5020
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Jaspers J, Sol W, Kersbergen A, Schlicker A, Guyader C, Xu G, et al.
Cancer Res
. 2014 Dec;
75(4):732-41.
PMID: 25511378
Pan- or multidrug resistance is a central problem in clinical oncology. Here, we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several...
22.
Urner M, Schlicker A, Roth Zgraggen B, Stepuk A, Booy C, Buehler K, et al.
Environ Sci Technol
. 2014 Oct;
48(23):13960-8.
PMID: 25343230
The effects of an exposure to three mass-produced metal oxide nanoparticles-similar in size and specific surface area but different in redox activity and solubility-were studied in rat alveolar macrophages (MAC)...
23.
Sieuwerts A, Willis S, Burns M, Look M, Meijer-Van Gelder M, Schlicker A, et al.
Horm Cancer
. 2014 Aug;
5(6):405-13.
PMID: 25123150
Recent observations connected DNA cytosine deaminase APOBEC3B to the genetic evolution of breast cancer. We addressed whether APOBEC3B is associated with breast cancer clinical outcomes. APOBEC3B messenger RNA (mRNA) levels...
24.
Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, et al.
Cell Rep
. 2014 Apr;
7(1):86-93.
PMID: 24685132
There are no effective therapies for the ~30% of human malignancies with mutant RAS oncogenes. Using a kinome-centered synthetic lethality screen, we find that suppression of the ERBB3 receptor tyrosine...
25.
Sun C, Wang L, Huang S, Heynen G, Prahallad A, Robert C, et al.
Nature
. 2014 Mar;
508(7494):118-22.
PMID: 24670642
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the...
26.
Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al.
Int J Cancer
. 2013 Jul;
134(3):552-62.
PMID: 23852808
In most colorectal cancer (CRC) patients, outcome cannot be predicted because tumors with similar clinicopathological features can have differences in disease progression and treatment response. Therefore, a better understanding of...
27.
Schlicker A, Beran G, Chresta C, McWalter G, Pritchard A, Weston S, et al.
BMC Med Genomics
. 2013 Jan;
5:66.
PMID: 23272949
Background: Colorectal cancer (CRC) is a heterogeneous and biologically poorly understood disease. To tailor CRC treatment, it is essential to first model this heterogeneity by defining subtypes of patients with...
28.
Huang S, Holzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, et al.
Cell
. 2012 Nov;
151(5):937-50.
PMID: 23178117
Inhibitors of the ALK and EGF receptor tyrosine kinases provoke dramatic but short-lived responses in lung cancers harboring EML4-ALK translocations or activating mutations of EGFR, respectively. We used a large-scale...
29.
Faria D, Schlicker A, Pesquita C, Bastos H, Ferreira A, Albrecht M, et al.
PLoS One
. 2012 Aug;
7(7):e40519.
PMID: 22848383
Despite the structure and objectivity provided by the Gene Ontology (GO), the annotation of proteins is a complex task that is subject to errors and inconsistencies. Electronically inferred annotations in...
30.
Frick R, Muller-Edenborn B, Schlicker A, Rothen-Rutishauser B, Raemy D, Gunther D, et al.
Toxicol Lett
. 2011 Jun;
205(2):163-72.
PMID: 21669262
Due to their physicochemical characteristics, metal oxide nanoparticles (NPs) interact differently with cells compared to larger particles or soluble metals. Oxidative stress and cellular metal uptake were quantified in rat...